Meeting
2022 ASCO Annual Meeting
Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114).
Authors
Sebastian Stintzing
Charité– Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany
Sebastian Stintzing , Ludwig von Weikersthal , Martin Fuchs , Florian Kaiser , Kathrin Heinrich , Dominik Paul Modest , Ralf Hofheinz , Thomas Decker , Armin Gerger , Stefan Angermeier , Holger Rumpold , Andreas Dickhut , Leopold Öhler , Birgit Gruenberger , Dora Niedersuess -Beke , Matthias Sandmann , Thomas Winder , Stefan Kasper , Gerald Prager , Volker Heinemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer - Neo-Adjuvant/Adjuvant
Clinical Trial Registration Number
NCT02934529
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3519)
DOI
10.1200/JCO.2022.40.16_suppl.3519
Abstract #
3519
Poster Bd #
313
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase III FIRE-4 study (AIO KRK-0114): Evaluation of first-line treatment efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC receiving the first cycle of treatment with chemotherapy only.
First Author: Sebastian Stintzing
Poster
2012 Gastrointestinal Cancers Symposium
Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).
First Author: Yutaka Ogata
Poster
2015 ASCO Annual Meeting
Genotype-directed phase II study of irinotecan dosing in metastatic colorectal cancer (mCRC) patients receiving FOLFIRI + bevacizumab: The GENIC study.
First Author: Grant Richard Williams
Poster
2011 ASCO Annual Meeting
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS mutated tumors in the randomized German AIO study KRK-0306.
First Author: S. Stintzing